Nuzefatide pevedotin clinical trials
How each study uses nuzefatide pevedotin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the nuzefatide pevedotin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2026 (2)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
BicycleTx Limited (3)
Often tested with
Tested in the same studies.
Zelenectide pevedotin (1) · CD137/Nectin-4 Bispecific-targeting Agent BT7480 (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test nuzefatide pevedotin.
- Dec 2026Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 ExpressionPhase 1/2 · BicycleTx Limited
Studies
Open first, then newest update. How each study uses nuzefatide pevedotin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)RecruitingPhase 2BicycleTx LimitedNCT07450859Written as nuzefatide pevedotin (BT5528)
- Bicycle Continued Access Protocol (BiCAP) for Participants Receiving a Bicycle Investigational ProductNot yet recruitingPhase 2BicycleTx LimitedNCT07681674Written as Nuzefatide pevedotin
- Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 ExpressionActive, not recruitingPhase 1/2BicycleTx LimitedNCT04180371Written as BT5528
Codes
What other systems call nuzefatide pevedotin · ClinicalTrials.gg INT016231
- UNII (FDA) CIT3DOS0DWNUZEFATIDE PEVEDOTINOne source FDA
- NCI Thesaurus C171425Nuzefatide PevedotinOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | CIT3DOS0DW | NUZEFATIDE PEVEDOTIN | One source FDA |
| NCI Thesaurus | C171425 | Nuzefatide Pevedotin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.